Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

XBiotech Inc. - Common Stock (NQ: XBIT )

3.250 -0.040 (-1.22%)
Streaming Delayed Price Updated: 9:30 AM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about XBiotech Inc. - Common Stock

< Previous 1 2 Next >
XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
XBiotech Pauses Rheumatology program
Findings from recently completed Rheumatoid Arthritis Study raise questions 
From XBiotech Inc.
Via GlobeNewswire
XBIT Stock Earnings: XBiotech Reported Results for Q2 2024
XBiotech just reported results for the second quarter of 2024. 
Via InvestorPlace
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
XBiotech reveals results from its Phase 1/Phase 2 1-BETTER Study for advanced pancreatic cancer, highlighting the safety and tolerability of Natrunix with the ONIVYDE + 5-Fluorouracil + Leucovorin... 
Via Benzinga
XBIT Stock Earnings: XBiotech Reported Results for Q1 2024
XBiotech just reported results for the first quarter of 2024. 
Via InvestorPlace
XBIT Stock Earnings: XBiotech Reported Results for Q4 2023
XBiotech just reported results for the fourth quarter of 2023. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Thursday
  Thursday saw 177 companies set new 52-week lows. 
Via Benzinga
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy 
From XBiotech Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
From XBiotech Inc.
Via GlobeNewswire
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
(Phase II Multicenter Study is Proceeding Well with High Anticipation) 
From XBiotech Inc.
Via GlobeNewswire
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
From XBiotech Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
From XBiotech Inc.
Via GlobeNewswire
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
From XBiotech Inc.
Via GlobeNewswire
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment 
From XBiotech Inc.
Via GlobeNewswire
Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Dow Jumps Over 100 Points; US Housing Starts Rise In April
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.37% to 33,135.37 while the NASDAQ rose... 
Via Benzinga
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
From XBiotech Inc.
Via GlobeNewswire
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after Stroke 
From XBiotech Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 79 companies reached new 52-week lows. 
Via Benzinga
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in France 
From XBiotech Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 1076 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 195 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 550 companies achieved new lows for the year. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 507 stocks hit new 52-week lows. 
Via Benzinga
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 429 stocks made new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 238 companies achieved new lows for the year. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 92 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.